MediWound (NASDAQ:MDWD) Posts Earnings Results, Misses Estimates By $0.01 EPS

MediWound (NASDAQ:MDWDGet Rating) released its quarterly earnings results on Tuesday. The biopharmaceutical company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.01), MarketWatch Earnings reports. MediWound had a negative return on equity of 3,540.43% and a negative net margin of 57.03%. During the same quarter in the prior year, the business posted ($0.10) EPS.

Shares of NASDAQ:MDWD opened at $1.77 on Wednesday. MediWound has a twelve month low of $1.25 and a twelve month high of $6.22. The stock’s 50 day moving average is $2.01 and its 200-day moving average is $2.39.

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Wells Fargo & Company MN lifted its stake in shares of MediWound by 12.3% in the fourth quarter. Wells Fargo & Company MN now owns 322,677 shares of the biopharmaceutical company’s stock valued at $762,000 after buying an additional 35,238 shares in the last quarter. Millennium Management LLC bought a new position in MediWound in the 4th quarter valued at about $57,000. Jane Street Group LLC acquired a new position in MediWound during the 3rd quarter valued at about $38,000. Morgan Stanley increased its holdings in MediWound by 12.4% during the 3rd quarter. Morgan Stanley now owns 85,947 shares of the biopharmaceutical company’s stock worth $287,000 after purchasing an additional 9,497 shares in the last quarter. Finally, Goldman Sachs Group Inc. purchased a new stake in shares of MediWound in the third quarter worth approximately $48,000. 13.58% of the stock is owned by institutional investors and hedge funds.

A number of brokerages have commented on MDWD. StockNews.com assumed coverage on shares of MediWound in a research report on Friday, May 13th. They set a “sell” rating on the stock. Zacks Investment Research downgraded MediWound from a “buy” rating to a “hold” rating in a report on Saturday, March 19th. Finally, Aegis cut their price target on MediWound from $9.00 to $7.00 and set a “buy” rating on the stock in a report on Monday, March 21st. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $5.69.

About MediWound (Get Rating)

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.

Read More

Earnings History for MediWound (NASDAQ:MDWD)

Receive News & Ratings for MediWound Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediWound and related companies with MarketBeat.com's FREE daily email newsletter.